Disseminated varicella-zoster virus infections following messenger RNA–based COVID-19 vaccination
Jordan T. Said, César A. Virgen, Christine G. Lian, Corey Cutler, Joseph F. Merola, Nicole R. LeBoeuf
Abstract
The novel messenger RNA (mRNA)–based COVID-19 vaccines protect individuals from SARS-CoV-2 infection and severe forms of the disease.1 Clinical trials data and observational evidence have reported diverse cutaneous responses to these vaccines, including local injection site erythema, urticaria, and morbilliform eruptions.2 Delayed localized hypersensitive reactions have also been reported; however, these do not preclude subsequent vaccination, emphasizing that serious cutaneous reactions to the vaccines are rare.
Topics & Concepts
MedicineVaccinationErythemaVirologyCoronavirus disease 2019 (COVID-19)ImmunologyVaricella zoster virusVirusMessenger RNADermatologyObservational studyDiseasePathologyInfectious disease (medical specialty)BiologyGeneBiochemistrySARS-CoV-2 and COVID-19 ResearchHerpesvirus Infections and TreatmentsDermatological and COVID-19 studies